Syenex
Synthetic biology platform for cell and gene therapies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
* | $10.0k | Grant | |
| Total Funding | 000k | ||
Related Content
Syenex is a biotechnology company that operates an open-science platform providing genetic medicine developers with access to targeted delivery technologies. Founded in 2022 by Jay Rosanelli, Professor Josh Leonard, and Jack Lin, the company aims to accelerate the development of cell and gene therapies. Rosanelli serves as CEO, and Leonard, a professor of Chemical and Biological Engineering at Northwestern University, is the Chief Scientific Officer. The company was launched to address the high costs and siloed innovation in the development of novel gene-delivery vehicles.
Based in Chicago, Illinois, Syenex is developing a mammalian synthetic biology platform to discover and commercialize targeted delivery vectors, such as extracellular vesicles and lentiviral vectors. The company's business model is inspired by the tech sector's "app store" concept, creating a universally accessible, continuously improving catalog of cell engineering and delivery technologies. This approach allows partners in biopharma and academia to focus their resources on therapeutic insights rather than re-developing delivery mechanisms. Syenex offers products like the UltraCell and RapidCell collections, which are designed to enhance vector production yield and simplify manufacturing processes. The company also provides its VivoCell Platform for precision in vivo delivery.
Syenex has raised a total of $13.7 million over two funding rounds, including a $5 million Series A in June 2022 and an $8.66 million Series B in January 2025, with investors including AlleyCorp and KdT Ventures. The company engages in partnerships to advance the field, collaborating with entities like CellFE, the Center for Translational Immuno-Oncology (CTMC), and ARTAN Bio to simplify manufacturing and accelerate programs from proof-of-concept to clinical studies.
Keywords: synthetic biology, cell therapy, gene therapy, genetic medicine, drug delivery, delivery vectors, extracellular vesicles, lentiviral vectors, biotechnology platform, open science, bioengineering, drug development, CDMO, GMP manufacturing, preclinical prototyping, biopharma, Jay Rosanelli, Josh Leonard